CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Quality of Life in CAR-T Cell Therapy.
Quality of Life in CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法改变了复发/难治性血液系统恶性肿瘤的管理，使B细胞急性淋巴细胞白血病、弥漫性大B细胞淋巴瘤及多发性骨髓瘤患者获得较高缓解率。虽然CAR-T 疗效已确立，生活质量（QoL）指标对于指导治疗决策、患者咨询和生存者计划的重要性日益增加。
多数CAR-T 患者在3个月内恢复至初始生活质量水平，这种改善在其他治疗选择中通常未见。随着CAR-T 领域发展，全面理解生活质量对于提供以患者为中心的照护至关重要。
本综述综合CAR-T 治疗接受者生活质量结局的现有证据，包括急性影响、恢复轨迹、与常规治疗的比较及优化生活质量的策略。
Background : Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning.
Objectives : Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape. Conclusions : This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
